Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium
Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
The decision to treat patients with denosumab was made independent of and before their enrolment in the study. No study drug was administered as part of the study.
Inclusion Criteria:
Exclusion Criteria:
Brain-Le-Comte, 7090, Belgium
Chênée, 4032, Belgium
Eisden Maasmechelen, 3630, Belgium
Mont-Godinne, 5530, Belgium
Paal-Beringen, 3583, Belgium
Thuilles, 6536, Belgium
Vlijtingen-Riemst, 3770, Belgium
Düsseldorf, 40223, Germany
Müllheim, 79379, Germany
München, 80335, Germany
München, 80634, Germany
München, 81675, Germany
Münster, 48149, Germany
Mönchengladbach-Rheydt, 41239, Germany
Nürnbrecht, 51588, Germany
Osnabrück, 49074, Germany
Saarbrücken, 66111, Germany
Völklingen, 66333, Germany
Würzburg, 97074, Germany
Chaidari, Athens, 12462, Greece
Maroussi, Athens, 15123, Greece